Morcellator Risks

Our firm is now accepting cases involving a medical product called a Morcellator used to treat uterine fibroids.  These devices were used during laparoscopic (minimally invasive) surgeries to treat uterine fibroids and during hysterectomies and myomectomies.

Unfortunately it has been discovered that the morecellation products pose risk of spreading unsuspected cancerous tissue beyond the uterus.  Most women will develop uterine fibroids at some point in their lives, although most cause no symptoms.  In some cases, fibroids can cause symptoms, such as heavy or prolonged menstrual bleeding, pelvic pressure or pain, and/or frequent urination which require medical or surgical therapy.  Many women choose to undergo laparoscopic hysterectomy or myomectomy and often these procedures are performed using a power morcellator.

Based on FDA analysis and data currently available, if laparoscopic power morcellation is performed in women with unsuspected uterine sarcoma, there is a risk that the procedure will spread the cancerous tissue within the abdomen and pelvis, significantly worsening the patient’s long-term survival.

If you or a loved one was treated with a morcellator and has been diagnosed with uterine sarcoma, leiomyosarcoma (LMS) or some other cancer that may have spread during a laparoscopic hysterectomy, a robotic hysterectomy or a laparoscopic myomectomy (uterine fibroid removal), contact our office immediately for a free consultation and evaluation.